Reportstack has announced a new market report on Multimmune GmbH - Product Pipeline Review - 2013 which provides data on the Multimmune GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from proprietary databases, Multimmune GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from Multimmune GmbH and industry-specific third party sources, put together by team of members.
Scope
- Multimmune GmbH - Brief Multimmune GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Multimmune GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Multimmune GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Multimmune GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Multimmune GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Multimmune GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Multimmune GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Multimmune GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Multimmune GmbH and identify potential opportunities in those areas.
This report is built using data and information sourced from proprietary databases, Multimmune GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from Multimmune GmbH and industry-specific third party sources, put together by team of members.
Scope
- Multimmune GmbH - Brief Multimmune GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Multimmune GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Multimmune GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Multimmune GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Multimmune GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Multimmune GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Multimmune GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Multimmune GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Multimmune GmbH and identify potential opportunities in those areas.
To view the table of contents and know more details please visit Multimmune GmbH - Product Pipeline Review - 2013 report.
Similar Reports:
No comments:
Post a Comment